Work

A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932).

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.5575

Authors: Alessandro Santin, Dana Marie Roque, Eric R. Siegel, Victoria M. Ettorre, Michelle Greenman, Sarah Ottum, Blair McNamara, Katya Papatla, Aparna Kailasam, Natalia Buza, Mitchell B. Clark, Pei Hui, Petter Dottino, Elena Ratner, Stefania Bellone

Institutions: Yale University, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Arkansas for Medical Sciences

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162489458

Cites:

Cited by:

Related to: